Vanda’s tradipitant falls short for gastroparesis as FDA requests ‘additional studies’

The FDA has issued a complete response letter to Vanda Pharmaceuticals indicating it cannot approve the company’s new drug application seeking approval for tradipitant as a treatment for gastroparesis.
According to a company press release, the FDA suggested that Vanda “conduct additional studies” for its neurokinin-1 receptor antagonist, tradipitant, a leading drug contender for gastroparesis.
The company fired back that the FDA has “generally disregarded the evidence provided,” and the design/duration suggestions for further studies were “inconsistent with

The FDA has issued a complete response letter to Vanda Pharmaceuticals indicating it cannot approve the company’s new drug application seeking approval for tradipitant as a treatment for gastroparesis.
According to a company press release, the FDA suggested that Vanda “conduct additional studies” for its neurokinin-1 receptor antagonist, tradipitant, a leading drug contender for gastroparesis.
The company fired back that the FDA has “generally disregarded the evidence provided,” and the design/duration suggestions for further studies were “inconsistent with